Cerebrospinal Fluid (CSF) Biomarkers Alzheimer's Disease (AD) and Non-AD Dementias

NCT01730430 | Completed

• 1 other identifier: Pro00033660
• Study Type: observational
• Target: 40
• Locations: 1 country
• Sites: 1

Brief Summary

To establish a cutoff value using a ratio of CSF tau to Aβ42 (tau/Aβ42) for distinguishing patients wth mild to moderate Alzheimer's disease (AD) from health elderly control subjects. The investigators hypothesize that a cutoff can be found that has at least 80% sensitivity and 60% specificity.

Conditions

Alzheimer's Disease; Dementias

Keywords

non-AD dementias; healthy elderly controls

Outcome Measures

Primary Outcomes (1)

• Ratio of CSF tau to Aβ42 (tau/Aβ42)

  CSF will be collected in clinic and shipped frozen to Merck's Clinical Development Lab for testing. Any remaining samples will be kept up to 20 years.

  CSF will be collected at Visit 1 (up to 30 days after the screening visit)

Study Arms (1)

Collection of CSF

1. Those with Alzheimer's disease 2. Those with non-Alzheimer's disease dementia 3. Healthy elderly volunteers

Eligibility Criteria

• Age: 55 Years - 85 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Duke Memory Disorders Clinic

You may qualify if:

• Each subject must be ≥ 55 to ≤ 85 years of age.
• Each subject must be able to read at a 6th grade level, as determined by the investigator, and must have a history of academic achievement and/or employment sufficient to exclude mental retardation.
• Each subject must have results of clinical laboratory tests, a physical examination, vital signs within normal limits or clinically acceptable to the investigator within 28 days prior to enrollment.
• Each subject (or legal representative) must sign the informed consent form after the scope and nature of the investigation have been explained to them, and before screening assessments.
• Must have a global Clinical Dementia Rating (CDR) score of 0.
• Must have a Mini-Mental State Examination (MMSE) score ≥ 28.
• Must have a Z-score ≥ -1.0 in each cognitive domain of memory (including delayed recall), language, executive function and attention, and visuoconstruction with neuropsychological tests of choice and adjustment for age, gender, and education level if indicated.
• Must meet the criteria for a diagnosis of probable AD based on both
• the National Institute of Neurological and Communicative Diseases and Stroke/Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria, and
• the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision (DSM IV TR) criteria for AD.
• Must have an MMSE score ≥ 15 and ≤ 26.
• Must have a clear history of cognitive and functional decline over at least one year that is either
• documented in medical records or
• documented by history from an informant who knows the subject well.
• Must have an MRI or CT scan that is consistent with a diagnosis of AD within 12 months prior to enrollment.

You may not qualify if:

• The subject has a Rosen modified Hachinski Ischemia Score \> 4.
• The subject has a known history of stroke.
• The subject has evidence of a clinically relevant or unstable neurological or psychiatric disorder (for AD subjects - other than AD).
• The subject has a history of alcoholism or drug dependency/abuse within the last 5 years before enrollment.
• The subject has an ongoing uncontrolled, clinically significant medical condition such that, in the judgment of the investigator, a subject's participation in the trial would pose a significant medical risk to the subject.
• The subject has participated within the last two months in a clinical trial of a novel therapeutic agent (e.g. bapineuzumab) or has ever been in a clinical trial of an AD vaccine.
• Pregnancy
• Standard clinical diagnostic criteria accepted by the field for non-AD dementias should be used by the Institution.

Sponsors & Collaborators

• Duke University: lead
• Merck Sharp & Dohme LLC: collaborator

Study Sites (1)

Duke Health Center at Morreene Road

Durham, North Carolina, 27705, United States

Location

Biospecimen

Retention: SAMPLES WITH DNA

Blood, urine and cerebral spinal fluid.

MeSH Terms

Conditions

Alzheimer Disease; Dementia

Condition Hierarchy (Ancestors)

Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Tauopathies; Neurodegenerative Diseases; Neurocognitive Disorders; Mental Disorders

Study Officials

• James Burke, MD, PhD

  Duke UMC

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: October 17, 2012
• First Posted: November 21, 2012
• Study Start: July 1, 2012
• Primary Completion: December 1, 2013
• Study Completion: December 1, 2013
• Last Updated: April 22, 2014

Record last verified: 2014-04

Locations

US (1)